Intra-Cellular Therapies (ITCI) Revenue & Revenue Breakdown
Intra-Cellular Therapies Revenue Highlights
Latest Revenue (Y)
$462.18M
Latest Revenue (Q)
$144.87M
Main Segment (Y)
Product
Intra-Cellular Therapies Revenue by Period
Intra-Cellular Therapies Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $462.18M | 85.51% |
| 2022-12-31 | $249.13M | 204.91% |
| 2021-12-31 | $81.71M | 262.65% |
| 2020-12-31 | $22.53M | 37071.49% |
| 2019-12-31 | $60.61K | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $245.84K | -25.66% |
| 2016-12-31 | $330.70K | 261.96% |
| 2015-12-31 | $91.36K | -84.17% |
| 2014-12-31 | $577.30K | -78.91% |
| 2013-12-31 | $2.74M | -12.22% |
| 2012-12-31 | $3.12M | - |
Intra-Cellular Therapies generated $462.18M in revenue during NA 2023, up 85.51% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Intra-Cellular Therapies Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $144.87M | 10.16% |
| 2023-12-31 | $131.51M | 4.53% |
| 2023-09-30 | $125.81M | 14.24% |
| 2023-06-30 | $110.13M | 16.25% |
| 2023-03-31 | $94.73M | 8.35% |
| 2022-12-31 | $87.43M | 21.65% |
| 2022-09-30 | $71.87M | 30.50% |
| 2022-06-30 | $55.07M | 58.46% |
| 2022-03-31 | $34.76M | 36.21% |
| 2021-12-31 | $25.52M | 18.10% |
| 2021-09-30 | $21.61M | 13.68% |
| 2021-06-30 | $19.01M | 22.00% |
| 2021-03-31 | $15.58M | 25.60% |
| 2020-12-31 | $12.40M | 68.33% |
| 2020-09-30 | $7.37M | 292.81% |
| 2020-06-30 | $1.88M | 112.56% |
| 2020-03-31 | $882.52K | 1355.98% |
| 2019-12-31 | $60.61K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $5.05K | -83.56% |
| 2017-09-30 | $30.75K | -73.20% |
| 2017-06-30 | $114.74K | 20.42% |
| 2017-03-31 | $95.29K | -2.66% |
| 2016-12-31 | $97.89K | 2144.27% |
| 2016-09-30 | $4.36K | -98.09% |
| 2016-06-30 | $228.44K | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $30.66K | 100.00% |
| 2015-09-30 | - | -100.00% |
| 2015-06-30 | $57.39K | 1631.22% |
| 2015-03-31 | $3.31K | -90.82% |
| 2014-12-31 | $36.11K | -70.98% |
| 2014-09-30 | $124.41K | -43.25% |
| 2014-06-30 | $219.24K | 30.66% |
| 2014-03-31 | $167.79K | -79.72% |
| 2013-12-31 | $827.53K | 23.89% |
| 2013-09-30 | $667.96K | 100.00% |
| 2013-06-30 | - | -100.00% |
| 2013-03-31 | $-129.64M | - |
Intra-Cellular Therapies generated $144.87M in revenue during Q1 2024, up 10.16% compared to the previous quarter, and up 165.69% compared to the same period a year ago.
Intra-Cellular Therapies Revenue Breakdown
Intra-Cellular Therapies Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Grant | $2.19M | $1.18M | $2.10M | $282.23K |
| Product | $462.18M | $249.13M | $81.71M | $22.53M |
Intra-Cellular Therapies's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (99.53%), and Grant (0.47%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $144.84M | $131.51M | $125.81M | $110.13M | $94.73M | $87.43M | $71.87M | $55.07M | $34.76M | $25.52M | $21.61M | $19.01M | $15.58M | $12.40M | $7.37M | $1.88M | $882.52K |
| Grant | $23.00K | $593.00K | $363.00K | $664.00K | $575.00K | $436.00K | - | $505.00K | $241.00K | $154.90K | $601.04K | $1.04M | $299.42K | $50.52K | - | $30.75K | $200.96K |
Intra-Cellular Therapies's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (99.98%), and Grant (0.02%).
Intra-Cellular Therapies Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMRX | Amneal Pharmaceuticals | $2.39B | $701.78M |
| NBIX | Neurocrine Biosciences | $1.89B | $590.20M |
| ALKS | Alkermes | $1.66B | $399.13M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $144.87M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DVAX | Dynavax | $232.28M | $73.80M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| CYTH | Cyclo Therapeutics | $1.08M | $123.10K |
ITCI Revenue FAQ
What is Intra-Cellular Therapies’s yearly revenue?
Intra-Cellular Therapies's yearly revenue for 2023 was $462.18M, representing an increase of 85.51% compared to 2022. The company's yearly revenue for 2022 was $249.13M, representing an increase of 204.91% compared to 2021. ITCI's yearly revenue for 2021 was $81.71M, representing an increase of 262.65% compared to 2020.
What is Intra-Cellular Therapies’s quarterly revenue?
Intra-Cellular Therapies's quarterly revenue for Q1 2024 was $144.87M, a 10.16% increase from the previous quarter (Q4 2023), and a 52.92% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $131.51M, a 4.53% increase from the previous quarter (Q3 2023), and a 50.41% increase year-over-year (Q4 2022). ITCI's quarterly revenue for Q3 2023 was $125.81M, a 14.24% increase from the previous quarter (Q2 2023), and a 75.05% increase year-over-year (Q3 2022).
What is Intra-Cellular Therapies’s revenue growth rate?
Intra-Cellular Therapies's revenue growth rate for the last 3 years (2021-2023) was 465.64%, and for the last 5 years (2019-2023) was 762401.44%.
What are Intra-Cellular Therapies’s revenue streams?
Intra-Cellular Therapies's revenue streams in c 23 are Grant, and Product. Grant generated $2.2M in revenue, accounting 0.47% of the company's total revenue, up 85.70% year-over-year. Product generated $462.18M in revenue, accounting 99.53% of the company's total revenue, up 85.51% year-over-year.
What is Intra-Cellular Therapies’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Intra-Cellular Therapies was Product. This segment made a revenue of $462.18M, representing 99.53% of the company's total revenue.